Combination therapy with direct acting antiviral agents (DAAs) without interferon (IFN) has emerged as a treatment for chronic hepatitis C because of its high overall sustained virologic response rates and favorable side effect profile as compared to that with interferon. We report the first case of drug-induced lung injury (DLI) associated with IFN-free therapy with the DAAs, daclatasvir (NS5A inhibitor) and asunaprevir (NS3/4A protease inhibitor). Although this combination therapy of DAAs has been considered to have fewer side effects than IFN, more attention should be paid to DLI as an important side effect.
Keywords: Asunaprevir; Chronic hepatitis C; Daclatasvir; Direct acting antiviral agents; Drug-induced lung injury.
Copyright © 2016 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.